National Centre for Pharmacoeconomics

National Centre for

NCPE Ireland

Obinutuzumab (Gazyvaro®) for Follicular Lymphoma

Obinutuzumab (in combination with bendamustine) followed by obinutuzumab maintenance is indicated for the treatment of patients with follicular lymphoma who did not respond or who progressed during or up to 6 months after treatment with rituximab or a rituximab-containing regimen.

Rapid Review

Commenced Completed Outcome
11/05/2016 31/05/2016 Full Pharmacoeconomic Evaluation Recommended

Pharmacoeconomic Evaluation

Commenced Completed Outcome
26/07/2016 25/01/2017 Reimbursement Not Recommended at the Submitted Price.


The HSE has approved reimbursement following confidential price negotiations October 2017.